Search for Clinical Trial Results

Encephalitis - 177 Studies Found
Status | Study |
Completed |
Study Name: Multicenter and Prospective Clinical Registry Study of Anti-N-methyl-D-aspartate Receptor Encephalitis in Beijing Area Condition: Anti-N-Methyl-D-Aspartate Receptor Encephalitis Date: 2015-05-10 |
Completed |
Study Name: Transcranial Direct Current Stimulation on Cortical Plasticity in Patients With Anti-NMDA Receptor Encephalitis Condition: Anti-NMDA Receptor Encephalitis Date: 2013-05-21 Interventions:
|
Active, not recruiting |
Study Name: Multicenter and Prospective Clinical Registry Study of Anti-N-methyl-D-aspartate Receptor Encephalitis in China Condition: Anti-NMDA Receptor Enphalitis Date: 2015-09-23 |
Not yet recruiting |
Study Name: Mechanisms of Auto-immune Encephalitis Condition: Autoimmune Encephalitis Date: 2016-07-04 Interventions: Other: Fundamental research |
Recruiting |
Study Name: Effect of Erythropoietin in Refractory Autoimmune Encephalitis Patients Condition: Autoimmune Encephalitis Date: 2016-12-21 Interventions: Drug: Erythropoietin three times per a week 100IU / k |
Recruiting |
Study Name: Effect of Vigabatrin in Refractory Autoimmune Encephalitis Patients Condition: Autoimmune Encephalopathy Date: 2016-12-13 Interventions: Drug: Vigabatrin 500 MG |
Not yet recruiting |
Study Name: IL-2 in Refractory Autoimmune Encephalitis Condition: Encephalitis Date: 2016-03-14 Interventions: Drug: Proleukin |
Recruiting |
Study Name: Antibodies Causing Epilepsy Syndromes: The ACES Study. Condition:
Date: 2016-06-07 Interventions: Biological: vena punction |
Active, not recruiting |
Study Name: Multicenter and Prospective Clinical Registry Study of Autoimmune Encephalitis in China Condition: Autoimmune Encephlitis in China Date: 2015-09-24 |
Active, not recruiting |
Study Name: Safety and Immunogenicity Study of Eastern Equine Encephalitis (EEE) Vaccine Condition: Eastern Equine Encephalitis Date: 2007-12-19 Interventions: Biological: Inactivated, Dried, TSI-GSD 104, EEE Subjects will receive 0.5ml SQ, as a two-dose primary s |